SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Granules India - Quaterly Results

23 Jan 2024 Evaluate
The revenue declined to Rs. 9844.85 millions for the quarter ended December 2023 as compared to Rs. 10323.91 millions during the corresponding quarter last year.Profit for the quarter ended December 2023 increased merely by2.08% to Rs. 1427.05  millions from Rs. 1398.00 millions.Operating Profit saw a handsome growth to 2475.50 millions from 2376.91 millions in the quarter ended December 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 9844.85 10323.91 -4.64 28149.00 29173.25 -3.51 39312.00 32384.37 21.39
Other Income 6.66 -9.29 -171.69 23.52 73.71 -68.09 99.32 175.11 -43.28
PBIDT 2475.50 2376.91 4.15 6144.31 6283.13 -2.21 8481.71 6621.60 28.09
Interest 197.79 117.56 68.25 522.13 245.55 112.64 386.74 163.52 136.51
PBDT 2277.71 2259.35 0.81 5622.18 6037.58 -6.88 8094.97 6458.08 25.35
Depreciation 361.59 383.21 -5.64 1074.38 1077.88 -0.32 1455.57 1261.61 15.37
PBT 1916.12 1876.14 2.13 4547.80 4959.70 -8.30 6639.40 5196.47 27.77
TAX 489.07 478.14 2.29 1160.78 1224.74 -5.22 1651.55 1331.31 24.05
Deferred Tax 34.50 -23.78 -245.08 81.89 -62.85 -230.29 -50.51 -3.76 1243.35
PAT 1427.05 1398.00 2.08 3387.02 3734.96 -9.32 4987.85 3865.16 29.05
Equity 242.37 242.04 0.14 242.37 248.29 -2.38 242.04 248.01 -2.41
PBIDTM(%) 25.15 23.02 9.22 21.83 21.54 1.35 21.58 20.45 5.52

Granules India Share Price

881.15 23.25 (2.71%)
09-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1938.85
Dr. Reddys Labs. 1269.80
Cipla 1441.70
Zydus Lifesciences 1159.85
Lupin 2502.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: